-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, E/BimKhu0ZzhDgx9IloonC6Mo73szXkDo9OzXp5WEci+zj1ihKJjs/mwUtOLATqP Mg8lXQAr+v/gsOPuaE3o+w== 0001179110-06-019131.txt : 20060928 0001179110-06-019131.hdr.sgml : 20060928 20060928195118 ACCESSION NUMBER: 0001179110-06-019131 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20060616 FILED AS OF DATE: 20060928 DATE AS OF CHANGE: 20060928 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PONIARD PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000755806 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 911261311 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 300 ELLIOTT AVENUE WEST STREET 2: SUITE 500 CITY: SEATTLE STATE: WA ZIP: 98119-4114 BUSINESS PHONE: 2062817001 MAIL ADDRESS: STREET 1: 300 ELLIOTT AVENUE WEST STREET 2: SUITE 500 CITY: SEATTLE STATE: WA ZIP: 98119-4114 FORMER COMPANY: FORMER CONFORMED NAME: NEORX CORP DATE OF NAME CHANGE: 19920703 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: McMahon Gerald PhD CENTRAL INDEX KEY: 0001290747 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-16614 FILM NUMBER: 061115247 BUSINESS ADDRESS: BUSINESS PHONE: 206-281-7001 MAIL ADDRESS: STREET 1: 300 ELLIOTT AVENUE WEST STREET 2: SUITE 500 CITY: SEATTLE STATE: WA ZIP: 98119-4114 4/A 1 edgar.xml FORM 4/A - X0202 4/A 2006-06-16 2006-06-20 0 0000755806 PONIARD PHARMACEUTICALS, INC. PARD 0001290747 McMahon Gerald PhD 300 ELLIOTT AVE WEST SUITE 500 SEATTLE WA 98119 0 1 0 0 Chief Executive Officer Stock Option 1.08 2006-06-16 4 A 0 1500000 1.08 A 2016-06-16 Poniard Commmon Stock 1500000 1500000 D Five hundred thousand shares vest in equal monthly installments of 1/48th per month from date of grant in accordance with the 2004 Incentive Compensation Plan. One million shares become exercisable in seven years from the date of grant. This amendment is to correct the number of derivative shares originally reported on June 20, 2006. The correct number of derivative shares is 1,500,000 shares, not 1,000,000 shares as originally reported on June 20, 2006. The vesting schedule also is corrected as detailed in footnote 1. /s/ Gerald McMahon 2006-09-28 -----END PRIVACY-ENHANCED MESSAGE-----